Caraco propels Detroit ops comeback

GMP consultants working for Caraco have put the finishing touches on a work plan that will let the drugmaker resume manufacturing at its Michigan facilities. The company now awaits FDA approval of the plan, in accordance with its consent decree.

Caraco maintains in its third quarter earnings report that it will pursue the release of some of the inventory seized by U.S. Marshals last June, as reported earlier. Raw materials worth some $8.1 million were opened "solely for the purpose of sampling," during the seizure, says Caraco. The remainder "would be difficult to recondition," the company tells its investors. The company created a $15.9 million reserve last December for this remaining inventory.

Based on its rehab progress to date, Caraco has started recalling some of the 430 employees it let go when manufacturing was halted. The returning employees, it says, are working on manufacturing-restart effort.

- see the Caraco announcement

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.